Black Diamond Therapeutics, Inc. (BDTX)
BDTX Stock Price Chart
Explore Black Diamond Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze BDTX price movements and trends.
BDTX Company Profile
Discover essential business fundamentals and corporate details for Black Diamond Therapeutics, Inc. (BDTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jan 2020
Employees
24.00
CEO
Mark A. Velleca
Description
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
BDTX Financial Timeline
Browse a chronological timeline of Black Diamond Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 Aug 2026
EPS estimate is -$0.18.
Earnings released on 7 May 2026
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%.
Earnings released on 16 Mar 2026
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 6 Nov 2025
EPS came in at -$0.15 surpassing the estimated -$0.22 by +31.82%.
Earnings released on 7 Aug 2025
EPS came in at -$0.19 surpassing the estimated -$0.25 by +24.00%.
Earnings released on 12 May 2025
EPS came in at $0.98 surpassing the estimated $0.02 by +4.80k%, while revenue for the quarter reached $70.00m , beating expectations by +150.00%.
Earnings released on 6 Mar 2025
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%.
Earnings released on 5 Nov 2024
EPS came in at -$0.28 surpassing the estimated -$0.37 by +24.32%.
Earnings released on 6 Aug 2024
EPS came in at -$0.36 surpassing the estimated -$0.39 by +7.69%.
Earnings released on 9 May 2024
EPS came in at -$0.35 surpassing the estimated -$0.44 by +20.45%.
Earnings released on 12 Mar 2024
EPS came in at -$0.34 surpassing the estimated -$0.47 by +27.66%, while revenue for the quarter reached $4.89m .
Earnings released on 6 Nov 2023
EPS came in at -$0.45 surpassing the estimated -$0.49 by +8.16%.
Earnings released on 11 Aug 2023
EPS came in at -$0.52 surpassing the estimated -$0.54 by +3.70%.
Earnings released on 9 May 2023
EPS came in at -$0.57 surpassing the estimated -$0.61 by +6.56%.
Earnings released on 9 Mar 2023
EPS came in at -$0.59 surpassing the estimated -$0.63 by +6.35%.
Earnings released on 8 Nov 2022
EPS came in at -$0.60 surpassing the estimated -$0.64 by +6.25%.
Earnings released on 9 Aug 2022
EPS came in at -$0.63 surpassing the estimated -$0.68 by +7.35%.
Earnings released on 11 May 2022
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%.
Earnings released on 17 Mar 2022
EPS came in at -$0.71 surpassing the estimated -$1.01 by +29.70%.
Earnings released on 8 Nov 2021
EPS came in at -$0.97 surpassing the estimated -$0.98 by +1.02%.
Earnings released on 12 Aug 2021
EPS came in at -$0.95 falling short of the estimated -$0.87 by -9.20%.
BDTX Stock Performance
Access detailed BDTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
